Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGEND001 Autologous Cell Infusion in Idiopathic Pulmonary Fibrosis
CTR20231266Phase 2Completed
- Sponsor
- Jiangxi Xianhe Medical Technology
- Start
- May 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous bronchial basal cells in idiopathic pulmonary fibrosis (IPF), sponsored by Jiangxi Xianhe Medical Technology. Started May 2023; status: completed.
02
Drugs
autologous bronchial basal cells
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20231266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231266.